Blog
RSS FeedPosted by Michael Wonder on 09 Mar 2022
NICE unable to provide guidance on a new use of lenalidomide
9 March 2022 - NICE is unable to make a recommendation on the use of lenalidomide for the treatment of patients ...
Posted by Michael Wonder on 08 Mar 2022
NICE yet to support the use of pralsetinib on the NHS
3 March 2022 - NICE publishes appraisal consultation document for a new medicine for certain patients with non-small-cell lung cancer. ...
Posted by Michael Wonder on 08 Mar 2022
NICE draft guidance does not recommend pembrolizumab plus chemotherapy for triple negative breast cancer
8 March 2022 - The evidence showed that pembrolizumab plus chemotherapy is more effective than paclitaxel or nab-paclitaxel, although the ...
Posted by Michael Wonder on 04 Mar 2022
Hundreds of patients to benefit from revolutionary lung cancer drug on the NHS
3 March 2022 - A revolutionary targeted drug for lung cancer will be made available to anyone who is eligible, ...
Posted by Michael Wonder on 03 Mar 2022
Over 500 people a year can access a new life extending lung cancer treatment after NICE recommends its use within the Cancer Drugs Fund
3 March 2022 - An innovative life-extending drug for treating mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults ...
Posted by Michael Wonder on 01 Mar 2022
ABPI response to England Rare Diseases Action Plan
28 February 2022 - England's Rare Disease Action plan is published today with details of how to improve diagnosis, care and ...
Posted by Michael Wonder on 27 Feb 2022
NHS treats first sickle cell disease patients with life changing drug
24 February 2022 - One of the first patients to access a ground-breaking treatment for sickle cell disease on the ...
Posted by Michael Wonder on 25 Feb 2022
NICE draft guidance recommends tucatinib for advanced breast cancer
25 February 2022 - Taken as two 150 mg tablets twice daily together with anti-cancer medicines trastuzumab and capecitabine, tucatinib ...
Posted by Michael Wonder on 24 Feb 2022
Once a day capsule for people with some forms of ovarian, fallopian tube and peritoneal cancer recommended for routine use in the NHS
24 February 2022 - The 20th cancer treatment to go through the Cancer Drugs Fund following a period of managed access ...
Posted by Michael Wonder on 22 Feb 2022
NICE recommends Albireo’s Bylvay (odevixibat) for all PFIC types
22 February 2022 - Positive NICE review completed in less than six months post MHRA approval. ...
Posted by Michael Wonder on 13 Feb 2022
First young children now taking life changing cystic fibrosis treatment on NHS
12 February 2022 - One of the first children to receive the game changing cystic fibrosis treatment, Kaftrio, on the ...
Posted by Michael Wonder on 10 Feb 2022
New life-extending drug for advanced womb cancer to be rolled out on the NHS
8 February 2022 - A 30 minute treatment, the first of its kind for advanced womb cancer, is being rolled ...
Posted by Michael Wonder on 09 Feb 2022
Topic selection process in health technology assessment agencies around the world: a systematic review
7 February 2022 - The purpose of this study was to systematically review the process for topic selection by health technology ...
Posted by Michael Wonder on 09 Feb 2022
NICE terminates yet another appraisal of daratumumab
9 December 2022 - NICE has attempted to appraise daratumumab six times; three have had to be terminated. ...
Posted by Michael Wonder on 09 Feb 2022
More than 100 people a year in England could benefit from new endometrial cancer treatment within the Cancer Drugs Fund
8 February 2022 - Innovative new drug for treating endometrial cancer in adults recommended by NICE as an option for use ...